Vosaroxin in combination with decitabine in newly diagnosed
Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome by Naval Daver, Hagop Kantarjian, Guillermo Garcia-Manero, Elias Jabbour, Gautam Borthakur, Mark Brandt, Sherry Pierce, Kenneth Vaughan, Jing Ning, Graciela M. Nogueras González, Keyur Patel, Jeffery Jorgensen, Naveen Pemmaraju, Tapan Kadia, Marina Konopleva, Michael Andreeff, Courtney Di. Nardo, Jorge Cortes, Renee Ward, Adam Craig, and Farhad Ravandi haematol Volume 102(10): 1709 -1717 September 30, 2017 © 2017 by Ferrata Storti Foundation
Survival and relapse-free survival in all patients on study. Naval Daver et al. Haematologica 2017; 102: 1709 -1717 © 2017 by Ferrata Storti Foundation
Protocol dosing algorithm. Naval Daver et al. Haematologica 2017; 102: 1709 -1717 © 2017 by Ferrata Storti Foundation
Characteristics of the study population (n=65). Naval Daver et al. Haematologica 2017; 102: 1709 -1717 © 2017 by Ferrata Storti Foundation
Response by baseline characteristics of the patients (n=65). Naval Daver et al. Haematologica 2017; 102: 1709 -1717 © 2017 by Ferrata Storti Foundation
Outcomes by induction dose of vosaroxin, N=65. Naval Daver et al. Haematologica 2017; 102: 1709 -1717 © 2017 by Ferrata Storti Foundation
Survival by vosaroxin induction dosage and age of the patients. Naval Daver et al. Haematologica 2017; 102: 1709 -1717 © 2017 by Ferrata Storti Foundation
Survival by baseline salient cytogenetic and molecular features. Naval Daver et al. Haematologica 2017; 102: 1709 -1717 © 2017 by Ferrata Storti Foundation
Survival by minimal residual disease status at time of response (A) Survival by minimal residual disease (MRD) at the time of response (± 3 months) as determined by multiplanar flow cytometry among the evaluable responders for all patients on study. Naval Daver et al. Haematologica 2017; 102: 1709 -1717 © 2017 by Ferrata Storti Foundation
Toxicities in the study patients (n=65). Naval Daver et al. Haematologica 2017; 102: 1709 -1717 © 2017 by Ferrata Storti Foundation
- Slides: 10